Integra Lifesciences Holdings (IART) Cash from Financing Activities (2009 - 2026)

Integra Lifesciences Holdings has reported Cash from Financing Activities for 18 years, with the latest figure at -$818000.0 in Q2 2026.

• Quarterly Cash from Financing Activities rose 96.13% year-over-year to -$818000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $21.6 million (up 268.21% YoY) and the FY2025 annual result came in at $28.3 million, down 88.09% from the prior year.
• Cash from Financing Activities retreated to -$818000.0 in Q2 2026 per IART's latest filing, from $8.3 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $358.7 million in Q1 2024 and troughed at -$162.7 million in Q1 2023.
• A 5-year average of -$11.6 million and a median of -$10.5 million in 2023 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities slumped 18852.21% in 2022, then soared 440.45% in 2025.
• Over 5 years, Cash from Financing Activities stood at -$97.7 million in 2022, then jumped by 92.95% to -$6.9 million in 2023, then retreated by 3.77% to -$7.2 million in 2024, then jumped by 440.45% to $24.3 million in 2025, then plunged by 103.36% to -$818000.0 in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$818000.0, $8.3 million, and $24.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.